An Open Label, Prospective, Single Center Study to Evaluate the Efficacy of Methyldopa & labetalol in Treatment of Patients with Pregnancy-induced hypertension

Author
Dr Deepanjali Lomte
Assoc. Prof. Dept. of Pharmacology

ABSTRACT
Background: Pregnancy-induced hypertension is associated with various adverse fetal and maternal outcomes. The use of anti-hypertensive drugs in pregnancy is controversial. We conducted a prospective study to evaluate the comparative effectiveness and safety of methyldopa and labetalol monotherapy in patients with pregnancy-induced hypertension.

Objective: To compare the efficacy & safety of Methyldopa and Labetalol on Blood pressure in Pregnancy-induced hypertension (PIH) patients.

Methods: Patients n= 60 pregnant women with blood pressure of 140/90 mm Hg or more with ≥1+ proteinuria and gestational age between 20-38 weeks were included in this prospective study. Cases were randomly divided into two groups of 30 each. Group I received methyldopa (n=30) and Group II received labetalol (n=20). Blood pressure was measured at 0, 6, 24, 48 and 72 h of initiation of antihypertensive drugs. Patients were also followed up for development of adverse drug effects during this period.

Results: Antihypertensive treatment with methyldopa was associated with reduction in systolic blood pressure (SBP) by 54 mmHg and diastolic blood pressure (DBP) by 30 mmHg at 72 h. For the same period treatment with labetalol was associated with reduction in SBP by 70 mmHg and DBP by 36 mmHg at 72 h.

Conclusions: Labetalol was more effective than methyldopa in controlling blood pressure in patients with pregnancy-induced hypertension.

Keywords: Antihypertensive, Pregnancy-induced hypertension(PIH), Pre-eclampsia, Methyldopa, Labetalol.

INTRODUCTION
Hypertensive disorders are the most common medical complications of pregnancy and are important causes of maternal and perinatal morbidity and mortality. Hypertension during pregnancy had been described in ancient literature as well. Preeclampsia, a life threatening complication of pregnancy is a condition that typically starts after 20th week of pregnancy and is related to increase blood pressure (BP≥140/90 mmHg) and protein in mother’s urine (urinary albumin protein ≥300 mg/24 h). Preeclampsia occurs in 5–8% of pregnancies worldwide, and is the second leading cause of direct maternal and fetal deaths. Hypertensive disorders during pregnancy are classified into 4 categories, as
recommended by the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy: 1) chronic hypertension, 2) preeclampsia-eclampsia, 3) preeclampsia superimposed on chronic hypertension, and 4) gestational hypertension (transient hypertension of pregnancy or chronic hypertension identified in the latter half of pregnancy). 3

The etiology of preeclampsia is still obscure, despite many attempts to identify possible causes. The clinical spectrum of preeclampsia ranges from mild to severe. Women with mild preeclampsia generally have no symptoms. Women with severe pre-eclampsia, or with very high blood pressure, may feel unwell, with symptoms such as headache, upper abdominal pain, or visual disturbances. 4

Pregnancies complicated by hypertension are associated with increased risk of adverse fetal, neonatal and maternal outcomes, including preterm birth, intrauterine growth restriction (IUGR), Perinatal death, acute renal or hepatic failure, antepartum haemorrhage, postpartum haemorrhage and maternal death. 5

The major goal of antihypertensive medication in PIH is to prevent or treat severe hypertension (generally defined as Blood Pressure (BP) of ≥160/110 mmHg) and its associated complications and to prolong pregnancy for as long as possible. 6

The antihypertensive drugs that may be used in pregnancy are methyldopa, beta blockers, calcium channel blockers and vasodilators. Methyldopa has been available for many years and is widely used. 7-12

The purpose of this study was to evaluate the comparative effectiveness and safety of methyldopa and labetalol monotherapy in patients with pregnancy-induced hypertension (PIH).

**Inclusion Criteria:**
1. Pregnant women aged ≥18, gestational week between 20 and 38 weeks with blood pressure of 140/90 mm Hg or more and ≥1+ proteinuria with urine dipstick test.

2. Pregnant women willing to give confirm consent for the study

**Excluding Criteria:**
1. Pregnant women with underlying chronic hypertension, history of antihypertensive medication in the current pregnancy & secondary hypertension.

2. Patients with molar pregnancies, multiple pregnancy, placenta previa.

3. Pregnant women with congenital anomalies, renal disease, hematological disease, heart disease and Diabetes.

After the approval of Institutional Ethics committee of Dr VPMC, Nashik, total 60 antenatal women with PIH, who first presented between 20 and 38 weeks of gestation & attending the outpatient department & antenatal ward at Civil Hospital Nashik, were included in the present study. The study was carried out during June 2011 to Jan.2012. Informed consent was obtained from all the patients before enrollment. Medical and obstetric history taking and physical examination were performed at the time of initial recruitment. Conventional sphygmomanometer was used for BP measurement and phase V Koratokoff sounds were used to define diastolic BP. The measurements were taken in the sitting position in a chair after 30 minutes rest. Urinary protein excretion was measured with urine dipstick test.

All the 60 cases enrolled in the study were randomly allocated into two groups. Group –I received Methyldopa (n=30) and Group II - received Labetalol (n=30). Methyldopa was started at a dose of 250-500mg twice daily while Labetalol was started at a dose of 100-400mg twice daily. All the patients were followed for 72hr. Blood pressure was measured at 0, 6, 24, 48
and 72 hr of initiation of antihypertensive drugs. Patients were also followed up for development of adverse drug effects during this period. Blood pressure data are presented diverse drug effects during this period. Blood pressure data are presented as mean for both treatment groups.

RESULTS
A total of 60 eligible patients were randomized to receive methyldopa ((n=30), Or labetalol ((n=30). Both groups had comparable baseline and demographic characteristics. The changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) are shown in figure 1 and figure 2 respectively.

Figure I

![Effect of Antihypertensive Drug on Systolic B.P.](image1)

Time

Effect of Antihypertensive Drug on Systolic B.P.

Figure II

![Effect of Antihypertensive drug on Diastolic B.P.](image2)

Time

Effect of Antihypertensive drug on Diastolic B.P.
Antihypertensive treatment with methyldopa was associated with reduction in systolic BP by 50 mmHg and diastolic BP by 30 mmHg at 72 h. For the same period treatment with labetalol was associated with reduction in systolic BP by 70 mmHg and diastolic BP by 36 mmHg at 72 hr. The common adverse effects reported are shown in figure 3. The commonest adverse effects noted were occipital headache (3-8%), postural hypotension (3-8%), tachycardia (2-3%), and depression (2-7%), nausea & vomiting. Depression was more common with both groups. Postural hypotension (10%) and vomiting (12%) were more commonly reported side effects with methyldopa group.

DISCUSSION
Pregnancy-induced hypertension is one of the major causes of maternal and foetal mortality and morbidity and as long as its exact cause is unknown, its prophylaxis will be uncertain. Many drugs have been used in the management of PIH in pregnancy.

The results of the present study demonstrate that antihypertensive drugs were very effective in reduction of systolic and diastolic blood pressure. In the past an increasing variety of hypertensive drugs have been used in treatment of PIH.

Unlike this study where two different antihypertensive drugs were effective as Monotherapy in controlling blood pressure other reports indicate the addition of another antihypertensive to control the blood pressure is frequently required.

One of the studies found it necessary to add hydralazine to both treatment regimens of oxprenalol and methyldopa for improved blood pressure control.12

Combination drug therapy confuses an already complex condition involving the mother and the foetus. The reported effects of antihypertensive drugs on the placental circulation and therefore oxygenation of the fetus are conflicting. One of the studies has reported a two-thirds incidence of small, for gestation age, infants born to women on oral antihypertensive drugs.13

Unlike other antihypertensive drugs labetalol reduces peripheral resistance without significantly reducing maternal cardiac output and pulse rate. This may be an additional factor in maintaining adequate placental perfusion and therefore foetal oxygenation in the treatment of pregnancy hypertension with labetalol.

Methyldopa is probably the most frequently used antihypertensive drug in pregnancy. Data suggest that the treatment of maternal hypertension with methyldopa may reduce the head circumference of infants where the drug has been prescribed between 16 and 20 weeks gestation.14
This may be the sensitive period for brain growth. This study confirms the previous findings that labetalol is an effective and safe drug for use in the control of blood pressure in pregnancy-induced hypertension. The low incidence of maternal and foetal side-effects together with the excellent prenatal outcome in a condition usually accompanied by a high maternal and foetal mortality and morbidity confirms its suitability for use during pregnancy.\(^{10}\)

The low incidence of pulmonary hyaline membrane disease suggests that it is the preferred drug in the treatment of pregnancy-induced hypertension.\(^{15}\)

**CONCLUSION**

The results of the present study concluded that both Methyl Dopa & labetalol are effective in controlling blood pressure in patients with PIH. But labetalol is more effective than methyldopa in controlling blood pressure in patients with pregnancy-induced hypertension.

**REFERENCES**

13. Welt SI, Dorminy JH 3rd, Jelovsek FR, Crenshaw MC, Gall SA. The effects of prophylactic Management and therapeutics on hypertensive Disease in pregnancy:
